Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2010 1
2011 1
2016 1
2017 1
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Histoprognostic markers role in colorectal cancer.
Bădulescu F, Mihai GM, Bădulescu A, Prejbeanu I. Bădulescu F, et al. Rom J Morphol Embryol. 2016;57(2):445-50. Rom J Morphol Embryol. 2016. PMID: 27516017 Free article.
Head and Neck Low Grade Chondrosarcoma-A Rare Entity.
Mireștean CC, Simionescu CE, Iancu RI, Stan MC, Iancu DPT, Bădulescu F. Mireștean CC, et al. Among authors: badulescu f. Diagnostics (Basel). 2023 Sep 22;13(19):3026. doi: 10.3390/diagnostics13193026. Diagnostics (Basel). 2023. PMID: 37835769 Free PMC article.
The Prognostic Value of Platelet-Lymphocyte Ratio, Neutrophil-Lymphocyte Ratio, and Monocyte-Lymphocyte Ratio in Head and Neck Squamous Cell Carcinoma (HNSCC)-A Retrospective Single Center Study and a Literature Review.
Mireștean CC, Stan MC, Iancu RI, Iancu DPT, Bădulescu F. Mireștean CC, et al. Among authors: badulescu f. Diagnostics (Basel). 2023 Nov 7;13(22):3396. doi: 10.3390/diagnostics13223396. Diagnostics (Basel). 2023. PMID: 37998532 Free PMC article.
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group. Gligorov J, et al. Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16. Eur J Cancer. 2017. PMID: 28625777 Clinical Trial.
Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study.
Boccia RV, Gordan LN, Clark G, Howell JD, Grunberg SM; Sancuso Study Group. Boccia RV, et al. Support Care Cancer. 2011 Oct;19(10):1609-17. doi: 10.1007/s00520-010-0990-y. Epub 2010 Sep 12. Support Care Cancer. 2011. PMID: 20835873 Free PMC article. Clinical Trial.